Silence Therapeutics (SLN)
(Delayed Data from NSDQ)
$18.27 USD
-0.04 (-0.22%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $18.33 +0.06 (0.33%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Silence Therapeutics PLC Sponsored ADR [SLN]
Reports for Purchase
Showing records 1 - 20 ( 33 total )
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Promising Divesiran Phase 1 Data in Polycythemia Vera Support Advancement to Phase 2
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Compelling End-of-Treatment Phase 2 Data in Lp(a) Support Advancement to Phase 3 Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Divesiran Phase 1 Data on Deck; Expect Promising Polycythemia Vera Data to Further De-Risk the Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
BioConnect Conference Takeaways: Nearing Multiple Catalysts in Underappreciated Pipeline Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
1Q24 Results; Phase 2 Readout in Lp(a) Program Expected in 2Q24 Should Support Advancement to Phase 3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Zerlasiran Shines in Phase 2 in Lp(a); Expect Phase 3 Program to Start in 2H24; 4Q23 Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Longer-Term Zerlasiran Phase 2 Data Support Advancement to Phase 3 Trial in CVD in 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Key Takeaways From Biotech Breakthroughs Lp(a) Event
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Underappreciated RNAi Platform Nearing Two Key Readouts Including in Potential Blockbuster Lp(a) Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SLN 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
3Q23 Results; Potential Blockbuster Lp(a) Program Progressing; Thalassemia Program Dropped; PT Down to $75; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
APOLLO Delivers Knockout Punch to Lp(a) in Multiple Dose Component; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
2Q23 Results; Nearing Multiple Data Readouts on Lead RNAi Programs in 4Q23 and Mid-2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
1Q23 Results; Multiple Pipeline Data Readouts Anticipated in 4Q23; Lp(a) Phase 2 Program Topline Data Expected Mid-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Management Meeting Highlights Focus on Lead Phase 2 RNAi Compounds Ahead of Next Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
4Q22 Results; 2023 Could Hold Key Clinical Progress For Lead Compounds; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Lead Programs Progressing to Phase 2; Updating SLN360 Assumptions Following Olpasiran Transaction; Lowering PT to $80
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Biotechnology - Ever Evolving Genetic Medicines
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Silence Therapeutics PLC Sponsored ADR
Industry: Medical - Drugs
Lead Compounds SLN360 and SLN124 to Shine in 2H22 With Data Readouts and Study Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P